ClinicalTrials.gg
RecruitingNCT05483283Updated Mar 10, 2026

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care

An interventional study of Empowerment and Navigation and SOC in Breast Cancer, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to female participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
30 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Breast Neoplasms by University of Illinois at Chicago — 7 open to participants now, 8 under way, 1 of them phase 3. Breast Neoplasms · University of Illinois at Chicago.

Planned enrollment
2nd of 15
600 · median 46
Started
2023
with 3 others
No phase
6 of 15
3 open now
Registered
8th of 15
by date

Among the 15 studies in Breast Neoplasms by University of Illinois at Chicago, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2023, is one of 6 with no phase, and was the 8th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 15 studies in Breast Neoplasms by University of Illinois at Chicago are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 30 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Breast Neoplasms by University of Illinois at Chicago, or all of them as a file.
02

Study summary

The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions with the study team across 3 consecutive weeks

Read the detailed description

The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions with the study team across 3 consecutive weeks. Sessions will be based on landline or cellphone calls. Within 1 week after each session, all Latina Aim 1 participants will receive copies of the multi-media materials (e.g., personalized plans) by text message or mail, depending on participants' preferences

Control Sessions will be as follows:

Session 1 Learning about Breast Cancer (BC) care uptake Targets the effects of Social Determinants of Heath (SDH) and genetic risk factors on Non-Latino White (NLW) Latino BC disparities Study staff will give personnel testimonials, empirical data and individual action plans behavior change and BC care uptake Session 2 Learning about Diet to promote BC prevention per the American Cancer Society (ACS) BC screening and prevention guidelines Session 3 Learning about Physical Activity to promote BC prevention

Empowerment and Navigation Sessions will be as follows:

Session 1 Learning about Breast Cancer (BC) care uptake Targets the effects of SDH and genetic risk factors on NLW/Latino BC disparities ACS BC screening and prevention guidelines Identify and address SDH and genetic risk factors Study staff will give personnel testimonials, empirical data and individual action plans for behavior change Session 2 Teaching about BC Targets the importance of sharing BC information and personal barriers \& preferred solutions to sharing BC information Study staff will give personnel testimonials and individual action plans for sharing information and role playing activities Session 3 Teaching about BC Targets opportunities \& skills in sharing BC information participants will give testimonials and relay empirical data. There will be a group discussion and plans for sharing information

There will be a post intervention BC survey call and an end of study BC survey call

Bicultural, bilingual study staff will engage participants in a 5-10 minute call/text every month to "check in" until the end of the study

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Aim 1

  1. female biological sex
  2. identification as Latina
  3. one genetic risk factor (i.e., personal history of breast cancer or family history of breast or ovarian cancer)
  4. one SDH risk factor, based on the American Cancer Society's definitions (e.g., perceived financial struggles; transportation difficulties; exposure to violence; housing challenges; social isolation/challenges)
  5. 30+ years old, based on American Cancer Society (ACS) screening guidelines for high risk populations
  6. No receipt of cancer genetic counseling AND no receipt of genetic testing

Aim 2

  1. female biological sex
  2. referral from Latina Aim 1 participants
  3. eligibility to obtain BC screenings, based on ACS guidelines (e.g., optional annual
  4. screenings at 40-44 years old, recommended annual screenings at 45-54 years old, every other year screening at 55 and older)
  5. self-report not attending Session #3 (as this will not be recorded by the staff)

Aim 3

  1. participant from Aim 1 or
  2. participant from Aim 2

Exclusion criteria

Exclusion Criteria:

Aim 1 and Aim 2 Not meeting at least one of the inclusion criteria

Aim 3

  1. Not a participant from Aim 1 or
  2. Not a participant from Aim 2
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Other
    Arm 1

    Empowerment and Navigation

    Other: Empowerment and Navigation

  • Other
    Arm 2

    Standard of Care (SOC)

    Other: SOC

Interventions

  • OtherEmpowerment and Navigation

    Empowerment and Navigation

  • OtherSOC

    SOC

06

What researchers measure

Primary outcomes

  1. Empower and navigation versus SOC

    Number of participants that undergo risk-based BC screening per ACS guidelines versus the control group

    Time frame: 4 years

  2. Empower and navigation versus SOC

    Number of participants that undergo recommended genetic services versus the control group

    Time frame: 4 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Sep 2027, 56 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 56 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2022
First posted
Aug 2, 2022
StartActual
Jan 18, 2023
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05483283
Responsible party
Yamile Molina (Prinicipal Investigator, University of Illinois at Chicago) — Principal investigator
First posted
Aug 2, 2022
Start date
Jan 18, 2023
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Mar 10, 2026

Study contacts

Yamile Molina, PhD
Contact
ymolin2@uic.edu
312-355-2679

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion